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Recent experimental evidence has provided strong support for the concept that at 
least two distinct populations of lymphoid cells cooperate in the production of humoral 
antibody. Synergism between thymus-derived (T cell)  1 and bone marow-derived (B 
cell) lymphocytes has been described in the induction of antibody synthesis against 
heterologous erythrocytes  (1-3),  serum  proteins  (4,  5),  and  hapten-protein conju- 
gates (6-8). Although both participating cell types can respond to specific antigenic 
stimulation  (9,  10),  actual  synthesis  of  exportable  immunoglobulin  is  apparently 
limited to cells of B lymphocyte lineage (11, 12). While T  cells therefore do not secrete 
detectable amounts of antibody, they appear in some cases to facilitate antibody pro- 
duction by B  cells. However,  the  mechanism  of  interaction between  these compo- 
nents is not well defined. 
We recently demonstrated that augmented immune responses similar to those after 
reexposure to the same antigen need not be specific (13). Inbred mice were primed with 
tetanus toxoid (TT);  later, their spleen cells were maintained in culture with sheep 
erythrocytes (SRBC).  The  addition of TT  (the  antigen used  initially for priming) 
to these cultures resulted in significant enhancement of the anti-SRBC plaque-form- 
ing cell (PFC) response as compared to aliquots cultured without TT. The addition of 
TT to comparable cultures of spleen cells from normal mice, or the addition of another 
antigen to TT-primed cultures, failed to produce enhancement of anti-SRBC plaques. 
Moreover,  augmentation  of the number  of plaques was  obtained by adding TT  to 
mixed cultures of  normal spleen cells plus thymocytes from  TT-primed mice  (14). 
These observations were consistent with the concept, first suggested by Davies et al. 
(11), that a mediator released from specifically  stimulated T cells acts on the antibody- 
forming  B  cells  to  increase  their  productive  response.  Supernatants  deri~ed  from 
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J; Career Investigator of the American Heart Association. 
1  Abbreviations used in this paper: B cell, bone marrow-derived lymphocyte; T cell, thymus- 
derived lymphocyte; PFC, plaque-forming  cell; SRBC, sheep erythrocytes; TT, fluid tetanus 
toxoid; FBS, fetal bovine serum;  EF, enhancing  factor; ThyT  +,  supernatants from primed 
thymocytes cultured with  tetanus  toxoid;  ThyT-,  supernatants from  primed thymocytes 
cultured without tetanus toxoid; SplTS  +, supernatants from primed spleen cells cultured with 
tetanus and sheep erythrocytes; SplT  +, supernatants from primed spleen ceils cultured with 
tetanus toxoid; Thy, thymocytes; Spl, spleen cells. 
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cultures of tetanus  toxoid stimulated,  TT-primed spleen ceils were tested for such an 
effector molecule. We  found  that  the  cell-free culture  fluid,  when  added  to  SRBC- 
stimulated,  normal  spleen cell cultures,  significantly  enhanced  the  anti-SRBC  PFC 
response  (15).  This activity was termed enhancing factor  (EF). 
The  purpose  of  this  paper  was  to  confirm  and  extend  the  finding  that  a 
humoral  factor,  released  upon  specific  interaction  of  antigen  with  a  primed 
population  of  T  cells,  can  increase  the  antibody  response  to  another  antigen 
present  in  the  system.  In  cell  cultures  containing  SRBC-stimulated  normal 
spleen  cells,  and  TT-primed  cells from either  thymus  or spleen,  enhancement 
of the anti-SRBC PFC  response occurred when 1 ng of TT was added,  although 
tenfold fewer thymocytes than  spleen cells were needed to produce comparable 
results.  Furthermore,  supernatants  of cultures  of thymocytes from TT-primed 
mice and  TT  were found  to contain  a  soluble  enhancing factor.  It was  absent 
from similar cultures of normal  thymocytes plus TT,  and from primed  thymo- 
cytes cultured without TT. 
Materials and Methods 
Immunization  of Mice.--8-wk old DBA/2 female mice (Jackson Laboratory, Bar Harbor, 
Maine)  were immunized  intravenously  with  10  Lf of fluid  tetanus  toxoid  (Massachusetts 
Department of Public Health, Division of Biologic Laboratories, Boston, Mass.).  Mice were 
shown to be primed by finding antitoxin in their serum, as previously described (13). 
Preparation of Spleen Call C~dtures.--Cell cultures were prepared from the spleens  of im- 
munized and normal mice 30-60 days after injection by the method of Mishell and Dutton 
(16) as modified by Mosier (17). Each culture contained 1 ml of cells (2 X  107) suspended in 
medium supplemented with 10% fetal bovine serum (FBS)  (Reheis Chemical Co., Kankakee, 
Ill.).  Cultures were fed daily with a  nutritional  supplement  (13) and  were stimulated with 
approximately 3 million SRBC on the day of culture (day 0). 1 ng of tetanus toxoid was added 
to half of these cultures on day  2.  The in vitro dose  of TT and  the time of addition were 
needed to elicit the optimal enhancement effect (13). Some cultures received only the priming 
antigen in the absence of SRBC stimulation. 
Preparation  of  Mixed  Lymphoid  Cultures.--Suspensions  of  TT-primed  thymoeytes  and 
normal thyrnocytes were prepared as described previously (14). Briefly, the two-thirds of the 
thymic lobes distal to the hilus were excised, care being taken to avoid fascial tags which might 
contain lymph node tissue.  All adherent connective tissue was removed. A number  (approxi- 
mately 10%)  of the DBA/2 mice used as thymus donors were injected intraperitoneaUy with 
0.2 ml of Pelikan ink (Gtinther Wagner, Hanover, Germany; lot No. Cll/1431A) diluted 1:1 
with saline, in order to reveal any parathymic nodes as found by Leckband and Boyse (18). 
None were found in DBA/2 mice.  In contrast,  in C3H mice treated  similarly, parathymic 
lymph nodes were easily detected in the connective tissue lateral to the thymic hilus. Thymus 
lobes were teased apart and treated similarly to the spleen cell suspensions.  Thymocytes were 
suspended  in complete medium  (13) to a  fiual concentration of 20 million cells/ml. Experi- 
mental cultures contained  10 million normal spleen cells and  10,  1, or 0.1  million primed or 
normal thymocytes. Parallel mixed cultures containing spleen cells from both immunized and 
normal mice were also prepared.  Mixed lymphoid cell cultures were stimulated with "IT and 
SRBC as described above and direct "19S" plaques enumerated on day 5 by a modification of 
the method of Jerne and Nordin (13). 
Preparation  of Supernatants.--On  day  5,  the  spleen cell culture  fluid was  collected and 
centrifuged to remove cells  (200 g,  10 min, 4°C). Superuatants  harvested from three to five ARNOLD  S.  RUBIN AND  ALBERT  H.  COONS  1503 
cultures per experimental group were stored at  --20°C until assayed for enhancing activity. 
In addition,  supernatants  were prepared  from short-term cultures  of thymocytes from TT- 
primed and normal animals by the methods described above. Thymocyte cultures containing 
20 million cells were stimulated with 1 ng of TT on day 0. Half of the cultures were unstimu- 
lated. Supernatants were collected sequentially from replicate cultures at 24, 48, and 72 hr and 
were treated as described earlier. 
Evaluation of Supernatant Activily.--Supernatants  from cultures of spleen cells or thymo- 
cytes  were assayed  for  the  ability  to augment  the  anti-SRBC  PFC  response  by  methods 
previously described  (15). Briefly, spleen cell cultures from normal mice were prepared and 
were stimulated with 3 million SRBC on day 0. Filtered supernatants, diluted in fresh medium, 
were added to such cultures on day 2. Direct plaques were counted on day 5. 
The degree of enhancement is expressed as the per cent difference between the numbers of 
plaques produced in cultures that received test supernatants,  compared to the PFC response 
of cultures  that  received the appropriate  dilution of a  normal control supernatant,  i.e.,  de- 
rived  from  normal  spleen  (or  normal  thymocyte)  cultures  not  receiving antigen.  Normal 
control supernatants  were used  as  base line controls  to  correct for any  enhancing activity 
provided by FBS, by constituents  released from dying cells,  or produced  by viable cells in 
response  to FBS foreign antigenic determinants.  Supernatants  assayed for enhancing factor 
included those derived from TT-primed spleen cell cultures that received (a) both tetanus and 
SRBC  (SPITS+),  or  (b)  tetanus  toxoid alone  (SplT+).  Supernatants  from cultures  of TT- 
primed  thymocytes  maintained  in  the  presence  or  absence  of  toxoid  were  also  tested  for 
enhancing factor. These supernatants were designated ThyT  + and ThyT-, respectively. Com- 
parable supernatants from cultures of unprimed, normal thymocytes were tested in parallel. 
Heat Treatments.--ThyT  + supernatants  were tested for the stability of enhancing factor 
to mild heat treatment.  One-half of each supernatant was heated at 56°C  for 30 rain.  Each 
aliquot was then diluted and the activity assessed  as described above. 
Dialysis.--ThyT + supernatants  were divided into two aliquots. One aliquot was dialyzed 
against 1000 volumes of isotonic saline for 24 hr at 4°C; an equal volume was kept cold, but 
not dialyzed. Treated and untreated aliquots were added to assay cultures and tested for the 
ability to amplify the anti-SRBC PFC response. 
Enzyme Treatments.--Supernatants  with enhancing activity (SplTS  +, SplT  +, and ThyT  +) 
were tested for their sensitivity to enzymatic degradation with deoxyribonuclease I  (DNAse, 
lot No. 5613; Worthington Biochemical Corp., Freehold, N. J.), ribonuclease A (RNAse, lot. 
No. 100C-8062; Sigma Chemical Co., St. Louis, Mo.), or protease (type VI, lot No. 71C-9020; 
Sigma  Chemical  Co.).  Supernatants  were  divided  into  two  aliquots.  DNAse,  RNAse,  or 
protease was added to one aliquot at a final concentration of 10 #g/ml. Supernatant-enzyme 
mixtures were mixed constantly  (1  hr,  37°C)  to  ensure adequate  contact between  enzyme 
and  substrate.  Treated and  untreated  aliquots were then assayed  for activity by the usual 
method. 
RESULTS 
Relative  Numbers  of Primed  Thymocytes  or Spleen  Cells  Needed  to  Produce 
Enhancement in Mixed Cell Cultures.--In  a  previous paper we reported  that at 
least some components  of antigen-specific immunological memory reside in the 
thymus of mice immunized 1-2 months earlier (14). Specific stimulation in vitro 
of thymocytes  from TT-primed  mice,  cultured  with  SRBC-stimulated  normal 
spleen  cells,  produced  a  significant  increase  in  the  anti-SRBC  hemolysin 
response  as  measured  by  plaque  formation  (14).  In  order  to  quantitate  the 
number of thymocytes necessary  to produce  this amplifying effect in vitro, cell 
mixtures  containing  10  million  normal  spleen  cells  and  graded  numbers  of 1504  SPECIFIC  ENHANCEMENT  OF  IMMUNE  RESPONSES 
syngeneic thymocytes from  mice immunized  with  TT were  stimulated  with 
SRBC  and  the  specific  priming  antigen.  A  parallel  study  was  performed 
substituting TT-primed spleen cells for the TT-primed thymocytes. The results 
of a representative group of experiments are shown in Table I. The addition of 
i ng of TT on day 2 to SRBC-stimulated, normal spleen cell cultures containing 
10 million or  1 million TT-primed thymocytes produced  an  average of 67 % 
and 89 % enhancement, respectively, of the anti-SRBC PFC response compared 
with similar cultures without the priming antigen (groups 1, 2 and 5, 6). The 
addition of TT to parallel cultures containing similar numbers of normal spleen 
cells  and  normal  thymocytes resulted  in  a  20%  and  18%  depression,  re- 
spectively, in the anti-SRBC response (groups 3, 4 and 7, 8). Although 1 million 
primed thymocytes could be triggered in vitro to produce nonspecific enhance- 
ment  of  the  PFC  response,  when  the  number  of  primed  thymocytes  was 
reduced to 1 X  10  ~ per culture, the addition of TT failed to elicit an augmented 
PFC  response  (groups  9  and  10).  Similar  additions  of  priming  antigen  to 
positive control  (groups  13 and  14)  and negative control cultures  (groups  15 
and  16),  from  representative  experiments,  produced  augmentation  or  slight 
depression,  respectively,  of  the  PFC  response,  as  previously  reported  (13). 
Cultured thymocytes alone, stimulated with TT and SRBC, failed to produce 
any  plaques  (13).  In  parallel  experiments,  in  which  10  million  TT-primed 
spleen cells were substituted for the 10 million primed thymocytes, the addition 
of 1 ng of toxoid resulted in a degree of augmentation of the anti-SRBC PFC 
response comparable to that seen in Table I  (groups 1 and 2, Table II). How- 
ever,  in  contrast  to  the  enhancement  seen  in  mixtures  of  1  million  primed 
thymocytes and 10 million normal spleen cells,  the addition of priming antigen 
to cultures with similar numbers of primed spleen cells and normal spleen cells 
resulted in a 14% depression in the anti-SRBC response (groups 5 and 6, Table 
II). Enhancement was consistently observed in representative positive controls, 
(groups 9  and  10),  while slight depression was  seen in  the  negative controls 
(groups 11 and 12). 
Release of Enhancing Factor  from  Thymocytes.--From the data in Table I  it 
is apparent that the addition of the specific priming antigen to primed thymo- 
c3tes maintained  in  the  presence of normal  spleen cells resulted in  the non- 
specific augmentation of the in vitro immune response to a non-cross-reacting 
(13)  antigen.  It was of interest to determine whether the mechanism of this 
enhancement  phenomenon  was  the  same  as  that  previously  reported  for 
specifically stimulated spleen cells (15), i.e., a  humoral factor released by the 
specific interaction of antigen with a primed population of T  cells can increase 
the productive antibody response of B cell lymphocytes reacting to a heterolo- 
gous  antigen.  Since  thymocytes  maintained  in  the  absence  of  a  supporting 
lymphoid cell population do not survive for extended periods of time in vitro  2 
(19), we cultured TT-primed and normal T cells from the thymus for 24-72 hr. 
2 Rubin, A. S. Unpublished observations. TABLE  I 
Effect on the Anti-SRBC PFC Response of Adding 1 ng of TT on Day 2 to Mixed Cultures of 10, 
1, or 0.1 Million TT-Primed Thymocytes and 10 Million Normal Spleen Cells 
Stimulated w#h SRBC on Day 0 
Cultured cells 
Group  (in millions) 
1  10 Primed Thy 
10 Normal Spl 
2  10 Primed Thy 
10 Normal Spl 
3  10 Normal Thy 
10 Normal Spl 
4  I0 Normal Thy 
10 Normal Spl 
5  1 Primed Thy 
10 Normal Spl 
6  1 Primed Thy 
10 Normal Spl 
7  1 Normal Thy 
10 Normal Spl 
8  1 Normal Thy 
10 Normal Spl 
9  0.1 Primed Thy 
10 Normal Spl 
10  0. I  Primed Thy 
10 Normal Spl 
11  0.1 Normal Thy 
i0 Normal Spl 
12  0.1 Normal Thy 
10 Normal Spl 
13  20 Primed Spl 
14  20 Primed Spl 
15  20 Normal Spl 
16  20 Normal Spl 
Anti-SRBC plaques per 106 recovered  cells 
Experiment 
1  2  3  4 
250  1793  1530  400 
1623 
' iill 
1583 
--17) 
1910 
1173 
(--4) 
1227 
947 
[(--8)  1--34) 
--  12500  1433 
+  1453  3347 
(61)  (56) 
--  903  2140 
+  660  2587 
!(--9)  (--3; 
--  726  2660 
1380 
(-15) 
1633 
973 
(37) 
710 
853 
(-33) 
1267 
2060 
(-13) 
2367 
2567 
(-6 
2720 
2737 
(34 
2050 
2173 
(--16 
2587 
260 
--32) 
380 
1800 
(91) 
940 
2260 
(--5) 
2390 
1647 
(12) 
1467 
1880 
(--19) 
2307 
1043 
(51) 
690 
797 
p* 
<0.005 
<0.005 
<0.001 
Nos.  in parentheses indicate degree of enhancement in per cent. 
* Calculated  by Student's t  test to  determine the significance of the difference between 
the mean enhancement produced in TT-primed cultures and the mean increase produced by 
the corresponding, similarly-treated, normal cultures. 
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TABLE  II 
Effect on the Anti-SRBC PFC Response of Adding 1 ng of TT on Day 2 to Mixed Cultures  of 10 
Million (or 1 Million) TT-Primed Spleen  Cells and 10 Million Normal Spleen  Cells 
Stimulated  with SRBC on Day 0 
Cultured  cells 
Group  (in millions) 
1  10 Primed Spl 
10 Normal Spl 
2  10 Primed Spl 
10 Normal Spl 
3  I0 Normal Spl 
10 Normal Spl 
4  10 Normal Spl 
10 Normal Spl 
5  1 Primed Spl 
10 Normal Spl 
6  1 Primed Spl 
10 Normal Spl 
7  1 Normal Spl 
10 Normal Spl 
8  1 Normal Spl 
10 Normal Spl 
9  20 Primed Spl 
10  20 Primed Spl 
11  20 Normal Spl 
12  20 Normal Spl 
Anti-SRBC plaques  per 10 6 recovered cells 
i  (61) 
--  1627 
+  1547 
(--42) 
--  2687 
I 
Jr  867 
(-18) 
--  1060 
+  1040 
(-30) 
--  1487 
q-  1740 
(5o) 
--  1160 
+  900 
(-2o) 
--  1120 
Experiment 
2  3  4 
2480 
(89) 
1313 
1833 
(1) 
1813 
1333 
(-35) 
2053 
1807 
(-3) 
1867 
1840 
(71) 
1073 
1380 
(-12) 
1567 
2553 
(61) 
1587 
1880 
(--13) 
2173 
2247 
(-15) 
2640 
1473 
(-21) 
1867 
2100 
(133) 
903 
2196 
(4) 
2103 
2040 
(10) 
1853 
1880 
(-8) 
2053 
2933  2827 
(58)  (42) 
1853  1993 
1673 
(6) 
1573 
2067 
(1) 
2047 
Average 
enhance- 
ment of 
anti-  P 
SRBC 
PFC 
response 
86% 
<0.OO5 
-12% 
-14% 
--15% 
55% 
<0.0Ol 
-6% 
See Table I  for explanatory footnotes. 
1 ng of TT  was added  at day 0.  Cell-free supernatants  were harvested  at daily 
intervals  and were assayed  for biological activity. Table III is a  typical  group 
of  experiments  which  show  the  reproducible  effect  on  the  anti-SRBC  PFC 
response  of adding  24 hr supernatants  on dav 2  to normal  spleen  cell cultures 
that  received SRBC  on day 0.  Addition of ThyT +  supernatants  derived from 
specifically-stimulated  primed  thvmocvtes  to  assay  cultures  resulted  in  a ARNOLD S.  RUBIN AND  ALBERT H.  COONS  1507 
TABLE  III 
Effect on the Anti-SRBC PFC Response of Adding 24-hr Thymocyte Culture Supernatants on 
Day 2 to Normal Spleen Cell Cultures That Received SRBC on Day 0 
Supernatant fluid from cultured 
thymocytes from primed or normal 
animals  Anti-SRBC plaques per 106 recovered cells 
Antigens  Final dilution of supernatant 
Exp.  Origin  added to 
culture  1 : 10  1:30  1 : 100 
Assay culture of normal spleen cells to which supernatant 
was added 
p* 
TT-primed  TT  1447  (--21)  1453  (--22)  2860  (+51):~ 
Normal  TT  2112  (+15)  1480  (--20)  1873  (--1) 
Normal  None  1840  1860  1893 
TT-primed  TT  1327  (+7)  1247  (--5)  1687  (+42) 
Normal  TT  1200  (--3)  1200  (--8)  1353  (+14) 
Normal  None  1240  1307  1190 
TT-primed  TT  1687  (--14)  2027  (+6)  3040  (+47) 
Normal  TT  1887  (--4)  1873  (--2)  1907  (--8) 
Normal  None  1973  1920  2073 
<0.005 
* Calculated by Student's t  test to determine the significance of the difference between 
the mean enhancement produced by the optimum dilutions of supernatants from TT-primed 
cultures and  the mean increase produced by the corresponding  dilutions of normal super- 
natants. 
Numbers in parentheses indicate the degree of enhancement  (in per cent) compared with 
the PFC response of normal cultures that had received supernatant from normal,  unstimu- 
lated cultures. 
significant increase in  the  anti-SRBC  plaque  response  compared  with  similar 
cultures  that  received  normal  control  supernatants.  The  average  increase 
obtained,  with  a  1:100  dilution  of  the  active  supernatant,  was  47%  (P  < 
0.005).  No such increase was found with culture medium from TT-stimulated 
normal thymocytes (Table III) or from unstimulated primed thymocytes (Fig. 
1).  Individual supernatants  contained varying amounts of enhancing  activity 
since  optimal  augmentation  of  the  hemolytic  plaque  response  was  obtained 
with either 1:30 or 1:100  dilutions of the culture fluid  (Tables III-VI). Dilu- 
tions other than  the optimal dilution generally depressed the PFC response or 
enhanced it to an insignificant degree. 
Kinetics  of  Rdease  of  Enhancing  Faclor.--Fig.  1  shows  the  results  of  a 
representative experiment in which supernatants from TT-primed thymocytes, 
maintained in the presence or absence of toxoid, were harvested from replicate 
cultures at 24-hr intervals and tested for enhancing activity. It can be seen that 
virtually all of the enhancing material was released from TT-stimulated primed 
thymocytes by 48 hr of culture,  although a  significant amount of activity was 
present in  the 24-hr  supernatants  (Table III). The  anti-SRBC  PFC  response 1508  SPECIFIC  ENHANCEMENT  OF  IMMUNE  RESPONSES 
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FIG. 1.  Kinetics of release of enhancing factor from TI'-primed thymocytes cultured with 
tetanus  toxoid. Assay of culture supernatants from replicate cultures at 24, 48, and 72 hr. 
($  O), ThyT  + supernatants; (O  'O), ThyT- supernatants. 
was not  significantly increased  by culture  fluid from TT-primed thymocytes 
maintained without TT  (Fig.  1,  lower curve). 
Effect of Heat Treatment on Activity of Thymocyte-Derived Enhancing Factor.-- 
Aliquots of ThyT  + supernatants,  harvested at 48 hr, were heated at 56°C  for 
30  rain  and  tested  for  the  ability  to  amplify the  production  of  anti-SRBC 
plaques in  assay cultures  compared to  the  enhancing  activity of similar, un- 
heated aliquots. Table IV (experiments 1 and 2) demonstrates that the activity 
present  in  the  ThyT  +  supernatants  was unaffected  by mild  heat  treatment. 
Diluted  aliquots  of heated  and  unheated  supernatants  produced  comparable 
degrees of enhancement of the PFC response when added on day 2 to normal 
spleen cell cultures that received SRBC on day 0. 
Effect  of  Dialysis  on  Activity  of  Thymocyte-Derived Enhancing  Factor.-- 
Supernatants  from 48-hr  cultures  of  TT-primed,  TT-stimulated  thymocytes 
were divided into aliquots. One aliquot was dialyzed against  1000 volumes of 
isotonic saline for 24 hr at 4°C, while the other was kept cold, but not dialyzed. 
The results from two independent experiments are shown in Table IV (experi- 
ments 3 and 4). It can be seen that the dialyzed and undialyzed supernatants 
were  equally  effective  in  amplifying  the  anti-SRBC  PFC  response  of  the 
assay cultures. 
Effect of DNAse, RiYAse, and Protease on Enhancing Faclor.--Culture fluids 
from TT-stimulated spleen cells or thymocytes were divided and treated with 
one of three enzymes (DNAse I, RNAse A, or protease) in an attempt to define 
the chemical nature of enhancing factor. One aliquot of each supernatant was 
mixed with  10/xg/ml of enzyme for 1 hr at 37°C,  while a  similar aliquot was 
left untreated.  Tables V  and  VI demonstrate  that  the  activity of enhancin~ ARNOLD  S.  RUBIN  AND  ALBERT  IL  COONS  1509 
TABLE IV 
Effect  on  the Anti-SRBC  PFC Response  of Adding  Heat-Treated  or  Dialyzed  48-hr  Culture 
Supernatants  on Day 2 to Normal Spleen  Cell Cultures  That Received SRBC on Da~ 0 
Supernatant  fluid from cultured 
thymocytes from primed or normal 
animals 
Exp.  Origin 
1  TT-primed 
TT-primed 
Normal 
2  TT-primed 
TT-primed 
Normal 
3  TT-primed 
TT-primed 
Normal 
4  TT-primed 
TT-primed 
Normal 
Antigen 
added  t, 
culture 
TT 
TT 
None 
TT 
TT 
None 
TT 
TT 
None 
TT 
TT 
None 
Assay culture of normal spleen cells to which 
supernatant  was added 
Supernatant  Anti-SRBC plaques per l0  s recovered  cell~ 
treatment 
Final dilution  of supernatant 
1:10  1:30  1,1no 
None 
Heat* 
None 
Heat* 
None 
Dialysis* 
None 
Dialysis~ 
1720  (--19) 
2020  (--5) 
2127 
2087  (--1) 
2127  (+1) 
2100 
2047  (+1) 
2433  (+20) 
2033 
1780  (+2) 
1967  (+12) 
1753 
2573  (+43) 
2607  (+45) 
1800 
2360  (+28) 
2400  (+30) 
1840 
2593  (+50) 
2520  (+46) 
1727 
1693  (-7) 
2073  (+14) 
1820 
1940 
2167 
1980 
2760 
2847 
(--2) 
(+9) 
(+64) 
(+69) 
1687 
2133  (+9) 
1887  (--4) 
1960 
2633  (+49) 
2647  (+50) 
1767 
See Table III for explanatory footnotes. 
* Supernatants heated at 56°C, 30 min. 
* Supernatants dialyzed against 1000 volumes of normal, isotonic saline for 24 hr at 4°C. 
factor  was  not  significantly affected  by  treatment  with  DNAse  or  RNAse, 
respectively,  whether  EF  was  derived  from  spleen  or  thymocyte  culture 
medium.  However,  exposure of active supernatants  to  protease resulted  in  a 
significant  decrease  in  their  ability to  augment  the  anti-SRBC  response  of 
normal  spleen  cells  (Tables V  and  VI).  As  a  control  for possible toxicity of 
protease  to  the  assay  cultures,  1  /zg  of  the  enzyme,  the  maximum  amount 
added with diluted supernatants  to  test cultures,  was added to  SRBC-stimu- 
lated spleen cell cultures. Similar numbers of plaques were obtained in cultures 
maintained with  or without  this  amount  of protease. Thus,  the reduction  of 
enhancing activity was due to enzymatic degradation of the factor, and not due 
to toxicity. 
DISCUSSION 
It  is  now  clearly  recognized  that  thymus-derived  lymphocytes  play  an 
important  functional  role  in  facilitating the  humoral  immune  response  of B 
ceils to  a  variety of antigens  (10,  20,  21).  But  the  actual  mechanism  of the 1510  SPECIFIC  ENHANCEMENT  OF  IMMUNE  RESPONSES 
TABLE  V 
Effect  on  the  Anti-SRBC  PFC  Response  of Adding  Enzyme-Treated,  Spleen  Cell  Culture 
Supernatants  on  Day  2  to  Normal  Spleen  Cell  Cultures  that  Received 
SRBC  on  Day  0 
Supernatant fluid from cultured 
spleen cells from primed 
or normal animals 
Assay culture of normal spleen cells to which 
supernatant was added 
Supernatant  Anti-SRBC  plaques  per 106 recovered cells  p 
treatment* 
Exp.  Origin  Antigens  added  Final dilution  of supernatant 
to culture 
1:10  1:30  1:100 
1  "IT-primed  TT, SRBC  None  527  (-42)  733  (-40)  1147  (+41) 
TT-prlmed  TT-SRBC  DNAse  853  (--6)  770  (--37)  1277  (+57) 
Normal  None  910  1213  813 
2  TT-primed  TT, SRBC  None  1243  (-11)  1190  (-3)  1450  (+42) 
TT-primed  TT, SRBC  DNAse  1490  (-}-7)  1470 (+19)  1450 (--42) 
Normal  None  1397  1233  1020 
3  TT-primed  TT, SRBC  None  2413  (--1)  3460 (@46)  3673  (+62) 
TT-primed  TT, SRBC  RNAse  2800 (+14)  3110 (+31)  3380 (+49) 
Normal  None  2447  2373  2273 
4  TT-primed  TT  None  1753 (-28)  2540  (+9)  3200 (+50) 
TT-primed  TT  RNAse  1827  (--25)  2493  (+7)  3180 (--49) 
Normal  None  2427  2327  2140 
5  TT-primed  TT, SRBC  None  1560 (--40)  2967  (--17)  3500 (+40) 
TT-prlmed  "IT, SRBC  Protease  1407  (--46)  2247  (--10)  2367  (--5) 
Normal  None  2620  2493  2500 
6  TT-primed  TT  None  1547  (--41)  2093  (-26)  3900 (+42) 
TT-primed  TT  Protease  2920 (+11)  3047  (+7)  2653  (--3) 
Normal  None  2627  2847  2740 
7  TT-primed  TT  None  1447  (--25)  1853  (--17)  2800 (+58) 
TT-primed  TT  Protease  2060  (+7)  1753  (--22)  2013  (+14) 
Normal  None  1927  2240  1773 
<0.010 
* Supernatants treated with 10 #g/ml of enzyme, 1 hr, 37°C. See Table III for explanatory footnotes. 
"helper cell" activity is not yet understood. A number of alternative experi- 
mental models have been proposed to explain the mechanism of T  cell-B cell 
interaction (22, 23). These hypotheses were summarized by Dutton et al.  (23) 
as  follows.  (a)  The  T  cell  concentrates  antigen  on  its  surface,  presuraably 
through  binding  to  specific receptor molecules,  and  presents  multiple  deter- 
minants  to  the  B  cell,  forming an  antigen-receptor bridge  between  the  two 
lymphocytes.  (b)  Surface  membrane  interaction  between  T  and  B  cells,  in 
addition to antigen-bridging between the cells,  is needed.  (c) The B  cell must 
receive two signals: one from its own receptor via antigen-binding and a second 
signal from the "carrier antibody" receptor on, or released by, the T  cell.  (d) 
Specifically activated  T  cells  release  a  nonspecific  chemical  mediator which 
triggers  B  cells  that  have already bound  antigen  through  receptors on  their ARNOLD S.  RUBIN  AND  ALBERT tI.  COONS  151I 
TABLE VI 
Effect  on  the Anti-SRBC PFC Response  of Adding  Enzyme-Treated,  Thymocyte  Culture 
Supernatants  on Day 2 to Normal Spleen  Cell Cultures  That Received SRBC on Day 0 
Supernatant fluid  from cultured 
thymoeytes from primed or normal 
animals 
Exp.  Origin 
1  TT-primed 
TT-primed 
Normal 
2  TT-primed 
TT-primed 
Normal 
3  TT-primed 
TT-primed 
Normal 
4  TT-primed 
TT-primed 
Normal 
5  TT-primed 
TT-primed 
Normal 
6  TT-primed 
TT-primed 
Normal 
Anti- 
gens 
aatded 
culture 
TT 
TT 
None 
TT 
TT 
None 
TT 
TT 
None 
TT 
TT 
None 
TT 
TT 
None 
TT 
TT 
None 
Supernatant 
treatment* 
None 
DNAse 
None 
DNAse 
None 
RNAse 
None 
RNAse 
None 
Protease 
None 
Protease 
Assay culture of normal spleen  cells  to 
which supernatant was added 
Anti-SRBC plaques per 106 recovered cells 
Final dilution of supernatant 
1:10  1:30  1:100 
913  (--16) 
913  (--16) 
1087 
2607  (--10) 
3020  (+4) 
29O0 
1473  (--21) 
1987  (+6) 
1867 
2310  (--18) 
2560  (-10) 
2833 
1667  (--44) 
1487  (--50) 
2993 
2087  (+2) 
1360  (--34) 
2053 
940  (--15) 
913  (--17) 
1100 
3040  (+9) 
2833  (+1) 
2800 
1453  (--21) 
1720  (--6) 
1833 
2910  (+9) 
2647  (--1) 
2667 
3216  (+16) 
2107  (--24) 
2767 
2820  (+44) 
1980  (+l) 
1953 
1373  (+45) 
1307  (+38) 
947 
4200  (+48) 
4000  (+41) 
2840 
2447  (+38) 
2407  (+36) 
1767 
3930  (+46) 
3870  (+43) 
2700 
4033  (+48) 
2753  (+l) 
2727 
2027  (--7) 
186o  (-15) 
2180 
<0.005 
* Supernatants treated with 10 #g/ml of enzyme,  1 hr, 37°C. See Table III for explana- 
tory footnotes. 
surface membranes. The result of such stimulation of B  cells is the production 
of immunoglobulin molecules which  carry the  same  specificity as that  of the 
receptor for antigen on the B  cell surface. An accessory cell, possibly the macro- 
phage, may also play an essential role in T  cell-B cell interactions (22, 24, 25). 
Our data strongly supports model d,  although  the other postulated mecha- 
nisms  of collaboration between  T  and  B  lymphocytes cannot  be  totally ex- 
cluded.  We  have  demonstrated  that  an  enhancing  factor  (EF)  is specifically 
released from presumably sensitized lymphoid cells by interaction with priming 
antigen.  Once  elicited, it can  augment  the immune  response  to  another,  un- 
related, antigen. The enhancing activity was generated in vitro by the addition 1512  SPECIFIC  ENHANCEMENT  OF  IMMUNE  RESPONSES 
of the specific antigen used for priming to cultures of spleen cells or thymocytes 
derived  from the  immunized  mice.  A  similar  addition  of priming  antigen  to 
.cultures  of normal  cells,  or  cells  from mice  primed  with  a  heterologous  im- 
munogen (15), failed to evoke the release of EF. The EF's found in the super- 
natant  medium of cultures  of either  spleen  cells,  or  thymocytes had  similar 
physicochemical characteristics. The activity of the mediator was nondialyzable 
and  unaffected  by  mild  heat  treatment  (56°C,  30  min)  or  treatment  with 
DNAse or RNAse. However, it was inactivated by exposure to protease.  Al- 
though  the  factor was  not  destroyed  by pancreatic  RNAse  or  DNAse,  this 
does not necessarily exclude the possibility that it can be inactivated by en- 
zymes with  other specificities or with  RNAse  A  or DNAse  I  under  different 
experimental  conditions.  We  conclude,  however,  that  the  soluble  factor  is 
protein in nature. 
The fact that an enhancing factor which can affect the productive response 
of B  cells is released  specifically from primed T  cells diminishes  the  need  to 
postulate  actual  antigen-bridging  between  the  two  classes of cells  as  a  prior 
requirement for activation of the B  cell component (models a  and b). With  a 
diffusable,  soluble  effector molecule,  close proximity between  the  cells would 
be sufficient. Alternatively, the mediator that we have described could be a T 
cell  receptor  (or carrier  antibody),  possibly complexed with  specific antigen. 
When bound to a receptor for antibody (26) or for antigen-antibody complexes 
(27)  found on the B cell surface, it might induce antibody synthesis in those B 
cells that have also bound  another antigen by specific antigen-receptor mole- 
cules.  This  double-hit  hypothesis is a  variation  of model  c  described  above. 
However,  the fact that active supernatants  were effective in  augmenting  the 
anti-SRBC PFC response when added to assay cultures on day 2, but not when 
added  on day 0  of a  5-day culture period  (15),  may argue against  this latter 
hypothesis.  By day 3,  substantial  numbers of PFC  are present in  the  spleen 
cell cultures  (16).  Thus, it is not inconceivable that most of the B  cells which 
can be affected by EF  are already past the  stage of differentiation  at which 
they could  be stimulated  sequentially  by antigen  and  a  complex.  Moreover, 
cellular interactions, both in vitro (28--30) and in vivo (31, 32), between mixed 
populations of histoincompatible lymphoid cells produce nonspecific augmenta- 
tion of immune responses similar to those we have described; indeed, it is likely 
that all these phenomena have a common mechanism which is associated with 
blast transformation. In fact, soluble factors produced by T  cells in a!logeneic 
cell  mixtures  have  been  reported  (33,  34).  Thus,  if  mere  contact  between 
allogeneic  cells is sufficient  to  trigger  an  elevated,  nonspecific  response,  it  is 
unlikely that an antigen-antibody complex, or an anti-carrier antibody derived 
from T  cells,  is involved in  these cell-to-cell interactions.  Furthermore,  a  dis- 
crete, adjuvant-like molecule, produced under a variety of clinical and experi- 
mental conditions, could explain many of the nonspecific anamnestic responses 
reported over the years (13). Other possible mechanisms of action of  EF have 
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A number of nonantibody mediators of cellular immunity have been reported 
in recent years (35). These soluble factors, which mediate in vitro phenomena 
correlated  with  delayed  hypersensitivity  observed  in  vivo,  nonspecifically 
amplify the activities of a small number of specifically stimulated lymphocytes. 
Effector molecules which apparently can regulate the humoral immune response 
have  also  been  described  (33,  34,  36-38).  Feldmann  and  Basten  (38)  have 
demonstrated  that  carrier-primed  T  cells,  stimulated  with  specific  hapten- 
carrier complex,  could collaborate with  similarly stimulated  B  lymphocytes 
to produce a response to the hapten  (DNP),  although  the lymphocytes were 
physically separated by a cell-impermeable membrane. B  cells were unable to 
respond to the complex in the absence of carrier-stimulated T  cells.  However, 
under similar conditions, the factor released specifically from carrier-primed T 
cells did not augment the immune response to donkey erythrocytes. Therefore, 
this factor may differ from EF since it only selectively enhanced the response 
of B  cells to specific determinants linked to the specificities recognized by T 
cells. 
Two T  cell-derived factors which  restored the immune  response of T  cell- 
depleted  spleen  cells  to  SRBC  have  recently been  described  (36,  37).  That 
found by Doria and his colleagues was released from thymocytes cultured with 
or without antigen (36). Another such material, reported b? Gorczynski et al., 
was  nondialyzable  and  was  released  by incubation  with  antigen  (37).  This 
latter material is very similar to the substance we have described. Schimpl and 
Wecker (33)  and Britton (34)  also found soluble factors which nonspecifically 
augmented the anti-SRBC PFC response but which were elicited by mixing T 
cells with lymphoid cells of a different H-2 type. These T  cell-replacing factors 
and  EF may have similar characteristics. However, the mediator of Britton 
(34)  can only be found in  the supernatants from 24-hr cultures of allogeneic 
cells, not in media from 48- to 120-hr cultures. Since EF persists for at least 72 
hr (Fig.  1),  there is a difference in the stability of the two effector molecules. 
Alternatively,  inhibitory  substances  which  mask  the  effect of  stimulatory 
factors produced in  allogeneic mixtures may also  be present in  the 48-hr to 
120-hr supernatants. Thus, of the soluble factors recently described, only EF 
has been at least partially characterized with respect to physicochemical prop- 
erties.  Consequently,  although  they  act  similarly  biologically,  whether  one 
or more of these mediators are identical awaits further experimentation. 
In Table I we have shown that antigenic stimulation affects a relatively small 
number of cells in the thymus in such a way that they respond specifically to it 
again on restimulation. This response on the part of primed thymocytes was 
manifest by the nonspecific enhancement of the response of normal spleen cells 
to an unrelated antigen. Thus, the addition of TT to mixed cell cultures con- 
taining  10 million  or  1 million,  but  not 0.1  million,  TT-primed thymocytes 
resulted  in  the  augmentation  of  the  anti-SRBC  hemolytic plaque  response. 
These data support the concept that a portion of T  cell memory resides in the 
immunocompetent  cells  of  the  thymus.  In  addition,  tenfold  fewer  primed 1514  SPECIFIC  ENHANCEMENT  OF  IM~IUNE  RESPONSES 
thymocytes than primed spleen ceils are needed to produce comparable degrees 
of enhancement.  Specific stimulation  of mixed  cultures  containing  1 million 
TT-primed thymocytes produced augmentation of the PFC response (Table I), 
whereas similar treatment of cultures containing 1 million primed spleen cells 
resulted  in  a  slightly depressed  plaque  response  (Table  II).  Mixed  cultures 
with 10 million primed spleen cells, when stimulated with TT, showed enhance- 
ment (Table II). These data suggest that there may be more antigen-reactive 
cells in the thymus than in the spleen, or that T  cells from the thymus, which 
are capable of responding to anamnestic stimulatian in vitro, are more reactive 
than similar types of memory cells from the spleen. On the other hand, there 
may be no real difference in the number of EF-producing cells from these two 
lymphoid organs. In fact, with respect to rosette-forming, antigen-binding cells, 
tenfold more are found in  the  spleen  than in  the  thymus  (39).  It is possible 
that the disparity in the number of spleen cells or thymocytes needed to produce 
comparable degrees of enhancement reflects the presence of a more balanced 
regulator}" control mechanism in the spleen in the form of inhibitor-releasing, 
lymphoid cells which can antagonize the effects of EF-releasing components. 
In  a  previous paper we  reported that  in  mixed  cell cultures  containing  1 
million thymocytes (or  10 million spleen cells) from TT-primed mice and  20 
million normal spleen cells, no enhancement could be elicited (14). It is apparent 
from Tables I  and II that when the priming antigen was added to cultures of 
1 million prhned  thymocytes (or  10 million primed  spleen cells)  mixed with 
only 10 million normal spleen cells, half the number used before, enhancement 
of the anti-SRBC  PFC  response was observed. Thus,  this number of primed 
thymocytes (or spleen cells) was reactive to anamnestic stimulation, but their 
activity was apparently masked by some component provided by the 20 million 
norma! spleen cells used in the earlier experiments. This masking phenomenon 
may be due to some type of soluble inhibitory molecule. The presence of such 
an inhibitor in the supernatants of specifically stimulated lymphoid cell cultures 
has been reported (15, 40). 
In  conclusion,  specific  antigenic  stimulation  of  thymocytes from  primed 
animals  results  in  the  release  of  a  soluble  factor  which  can  nonspecifically 
amplify the humoral immune response of normal spleen cells that are responding 
to  a  heterologous, non-cross-reacting antigen.  A  factor with  similar physico- 
chemical properties is also released in vitro by anamnestic stimulation of primed 
spleen cells. The mediator is most likely protein in nature. An effector molecule 
such as the one we have described may mediate cellular interactions between 
T  cells and B cells in the induction of antibody synthesis. 
SUMMARY 
In short-term cultures of thymocytes from tetanus toxoid-immunized mice, 
the addition of 1 ng of tcxoid generated the release of a soluble factor which was 
capable of enhancing the imnmne response to a heterologous immunogen. The ARNOLD  S.  RUBIN  AND  ALBERT  H.  COONS  1515 
addition of supernatants from such cultures to assay cultures of sheep erythro- 
eyte-stimulated normal spleen cells produced a significant augmentation of the 
hemolytic plaque response. Culture fluid from similar cultures of normal thymo- 
cytes or primed thymocytes cultured without the priming antigen were inactive. 
The enhancing factor was nondialyzable, heat stable  (56°C,  30 rain), resistant 
to DNAse and RNAse, but was inactivated by protease. A factor produced by 
specifically stimulated primed spleen cells had similar characteristics. In toxoid- 
stimulated,  mixed cell  cultures  containing primed  thymocytes or spleen  cells 
and normal spleen cells, tenfold fewer thymocytes than spleen cells were needed 
to produce a comparable degree of enhancement of the anti-sheep erythrocyte 
plaque-forming cell response. 
We thank Miss Celia Velletri for excellent technical help. 
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